A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals.

[1]  B. Nordestgaard,et al.  Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population , 2019, Annals of neurology.

[2]  B. Nordestgaard,et al.  Nonfasting versus fasting lipid profile for cardiovascular risk prediction. , 2019, Pathology.

[3]  Deepak L. Bhatt,et al.  Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease , 2019, JAMA.

[4]  C. V. van Duijn,et al.  Metabolic profiling of intra- and extracranial carotid artery atherosclerosis. , 2018, Atherosclerosis.

[5]  B. Nordestgaard,et al.  Antiplatelet therapy: Pharmacogenomic approach to tailor drug therapy , 2018, Nature Reviews Cardiology.

[6]  I. Ramasamy.  Update on the laboratory investigation of dyslipidemias. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[7]  R. Collins,et al.  Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke , 2018, Journal of the American College of Cardiology.

[8]  B. Nordestgaard,et al.  Remnant Cholesterol and Myocardial Infarction in Normal Weight, Overweight, and Obese Individuals from the Copenhagen General Population Study. , 2018, Clinical chemistry.

[9]  D. Lawlor,et al.  Metabolic characterization of menopause: cross-sectional and longitudinal evidence , 2017, bioRxiv.

[10]  B. Nordestgaard.  A Test in Context: Lipid Profile, Fasting Versus Nonfasting. , 2017, Journal of the American College of Cardiology.

[11]  Dan J Stein,et al.  Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.

[12]  Audrey Y. Chu,et al.  Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol , 2017, Journal of the American Heart Association.

[13]  Debbie A Lawlor,et al.  Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies , 2017, American journal of epidemiology.

[14]  J. Borén,et al.  The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity , 2016, Current opinion in lipidology.

[15]  B. Nordestgaard,et al.  Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease. , 2016, Clinical chemistry.

[16]  M. Pirinen,et al.  Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA , 2016, Nature Communications.

[17]  B. Nordestgaard.  Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.

[18]  B. Nordestgaard,et al.  Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. , 2015, Clinical chemistry.

[19]  Pasi Soininen,et al.  Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. , 2015, Circulation. Cardiovascular genetics.

[20]  T. Lehtimäki,et al.  A metabolic view on menopause and ageing , 2014, Nature Communications.

[21]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[22]  B. Nordestgaard,et al.  Remnant cholesterol and ischemic heart disease , 2014, Current opinion in lipidology.

[23]  B. Nordestgaard,et al.  Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. , 2014, Pharmacology & therapeutics.

[24]  Toomas Haller,et al.  Biomarker Profiling by Nuclear Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality: An Observational Study of 17,345 Persons , 2014, PLoS medicine.

[25]  J. Brezmes,et al.  Human serum/plasma lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia. , 2013, Progress in nuclear magnetic resonance spectroscopy.

[26]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[27]  Samia Mora,et al.  Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women , 2009, Circulation.

[28]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[29]  V. Saraswathi,et al.  The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages Published, JLR Papers in Press, April 25, 2006. , 2006, Journal of Lipid Research.

[30]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[31]  R. D'Agostino,et al.  Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. , 2004, Clinical chemistry.

[32]  B. Nordestgaard.  The vascular endothelial barrier — selective retention of lipoproteins , 1996, Current opinion in lipidology.

[33]  B. Nordestgaard,et al.  Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[34]  R. Wootton,et al.  Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[35]  B. Nordestgaard,et al.  Intermediate density lipoprotein levels are strong predictors of the extent of aortic atherosclerosis in the St. Thomas's Hospital rabbit strain. , 1991, Atherosclerosis.

[36]  D. B. Zilversmit,et al.  Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. , 1988, Journal of lipid research.

[37]  D. B. Zilversmit,et al.  Hyperglycemia in normotriglyceridemic, hypercholesterolemic insulin-treated diabetic rabbits does not accelerate atherogenesis. , 1988, Atherosclerosis.

[38]  B. Nordestgaard,et al.  Reduced Atherogenesis in Cholesterol‐fed Diabetic Rabbits: Giant Lipoproteins Do Not Enter the Arterial Wall , 1988, Arteriosclerosis.

[39]  P. Wahl,et al.  Distribution of lipoproteins triglyceride and lipoprotein cholesterol in an adult population by age, sex, and hormone use- The Pacific Northwest Bell Telephone Company health survey. , 1981, Atherosclerosis.

[40]  D. Jacobs,et al.  Lipoprotein‐Cholesterol Distributions in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study , 1980, Circulation.

[41]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.